Recombinant Tuberculosis Vaccine
The recombinant tuberculosis vaccine (AEC/BCO2) developed by Zhifei is composed of recombinant mycobacterium tuberculosis protein expressed in E. coli and novel biological adjuvant system developed by the company and is produced after purification and lyophilization. It is indicated for the prevention of latent tuberculosis infection (LTBI).
Influenza Virus Split Vaccine
The influenza virus split vaccine developed by Zhifei is made by inoculating chicken embryos with WHO-recommended influenza virus strains, and is prepared by culture, inactivation and purification. It has low protein, low egg albumin residue and low endotoxin, which is safer to use.
MenACYW135 conjugate vaccine
This candidate is developed based on the marketed product — MenACYW135 polysaccharide vaccine, with tetanus toxoid as the protein carrier. It is indicated for infants and children aged 3 months and above to prevent infectious disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135, providing earlier protection for younger infants and toddlers.
15-valent Pneumococcal conjugate vaccine (PCV15)
This candidate is indicated for active immunization to prevent invasive disease caused by 15 serotypes of Streptococcus pneumoniae included in this vaccine. This candidate is the first of its kind — comparing with PCV13, it covers two extra serotypes that are prevalent among Chinese population and thus having a broader protection. This project has been supported by the nation’s Major Project of New Medicine Development.
Shigella vaccine (bivalent)
The bivalent shigella vaccine the company is developing is indicated for the prevention of bacterial shigella caused by shigella flexneri and shigella sonnei. It is the first conjugate vaccine developed that can prevent infections caused by both shigella flexneri and shigella sonnei. This Class I New Drug is supported by the nation’s Major Project of New Medicine Development and is protected by multiple patents.
EV71 inactivated vaccine
This candidate is indicated for infants and children aged 6 months and above. After injection, the vaccine can stimulate the body to generate immunity against enterovirus 71 to prevent hand, foot and mouth’s disease caused by this virus.
BCG vaccine for intradermal injection
The company is developing a BCG vaccine for intradermal injection using Bacillus Calmette–Guérin (BCG) through culturing, collecting of bacteria and freeze drying, for preventing tuberculosis.
Component diphtheria pertussis tetanus vaccine
The company is developing a component diphtheria pertussis tetanus vaccine by purifying and detoxicating different antigens of pertuss to make stock solution, with which diphtheria toxoid stock solution and tetanus toxoid stock solution are mixed and to which aluminum adjuvant is added, to produce the vaccine for preventing pertussis, diphtheria and tetanus.
Freeze-dried rabies vaccines for human use (MRC-5 cells)
The company is developing a freeze-dried rabies vaccine for human use (MRC-5 cells) using the fixed virus seed of rabies virus, where the virus seed is inoculated to MRC-5 cells, which are then cultivated and subjected to culturing, harvesting, concentrating, virus inactivating, purifying and freeze-drying to produce the vaccine for preventing rabies.
Freeze-dried rabies vaccines for human use (Vero cells)
The company is developing a freeze-dried rabies vaccine for human use (Vero cells) using the fixed virus seed of rabies virus, where the virus seed is inoculated to Vero cells, which are then cultivated and subjected to culturing, harvesting, concentrating, virus inactivating, purifying and freeze-drying to produce the vaccine for preventing rabies.
Tetravalent influenza virus split vaccine
The company is developing a tetravalent split influenza virus vaccine using virus strains A H1N1, A H3N2, B Vicoria and B Yamagata recommended by WHO, where the strains are inoculated to embryonated eggs, which are then cultivated for extraction of virus solution which is further inactivated, purified and split to produce the vaccine for preventing influenza caused by the virus strains.
Tetravalent recombinant norovirus vaccine (Pichia pastoris)
The company is developing a tetravalent recombinant norovirus vaccine using the Pichia pastoris expression system, where the system is used to establish the VLP recombinant engineered bacteria for expressing norovirus epidemic strains, which are then cultivated and purified in large scale to produce vaccine for preventing acute gastroenteritis caused by norovirus.